Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

We came across a bullish thesis on Hims & Hers Health, Inc. (HIMS) on Substack by Antonio Linares. In this article, we will ...

Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads ...

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company ...

Hims & Hers Health Inc. (HIMS) is facing increased skepticism from investors and analysts over the sustainability concerns of ...

It is hard to get excited after looking at Hims & Hers Health's (NYSE:HIMS) recent performance, when its stock has declined 34% over the past month. However, a closer look at its sound financials ...

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Hims shares gained as much as 14% in New York, their biggest gain since Feb. 19.

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Hims & Hers Health, Inc. (HIMS) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

NYSE HIMS opened at $29.73 on Tuesday. The company has a market capitalization of $6.60 billion, a price-to-earnings ratio of 67.56 and a beta of 1.37. Hims & Hers Health, Inc. has a 12 month low ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.